Clinical trials: COVID-19; Immunity
SARS-CoV-2, SARS-CoV-2 (COVID-19) Infection
Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region
The aim of the study is to find the proportion of people in the population of the Olomouc Region with the presence of IgG (or IgM) antibodies against the S and N antigens of the SARS-CoV-2 virus, therefore people who have already…
- Trial name
- NCT07387211
- Testing
- Blood sampling, Gargle sampling, Questionnaire completion
- Where
- Czechia
- Volunteers
- 2,484 people, healthy volunteers welcome
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
Covid19
Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).
An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic strain on the immune response in participants positive for SARS-CoV-2 infection.
- Trial name
- PROVID (NCT04937556)
- Testing
- Probiotic: Lactobacillus salivarius + Vit D + Zinc
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- ProbiSearch SL
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Cancer
Immune Response to the COVID-19 Vaccine
Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
- Conditions
- Covid19, Cancer, Malignancy, Vaccine Response Impaired
- Trial name
- NCT04936997
- Testing
- SARS-COV2 Pfizer Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arizona
Chronic Lymphocytic Leukemia, COVID-19
Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL
Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy affecting older adults. CLL patients are immunocompromised by the disease itself and by several of its therapies.
- Trial name
- PACE-CLL (NCT05465876)
- Testing
- EVUSHELD
- Where
- Canada
- Sponsor
- Sunnybrook Health Sciences Centre
COVID-19
A Longitudinal Study of COVID-19 Sequelae and Immunity
Background: COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract. Some people who get COVID-19 have only mild symptoms.
- Trial name
- NCT04411147
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV-2 Viraemia
Neutralizing Power of Serum Antibodies - 2
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies.
- Conditions
- COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination
- Trial name
- PNAS-2 (NCT07085611)
- Testing
- Sample collection (blood and optional nasal swab)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
COVID-19
Evaluating the Response of the Immune System of People With Long COVID (Post SARS-CoV-2)
Many people who have had COVID 19 continue to experience symptoms long after they have recovered from the acute infection. This study will examine the clinical symptoms of people with "Long COVID" and measure various markers of…
- Trial name
- LCRC (NCT05131594)
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Huntington Memorial Hospital
COVID 19 Vaccine
Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)
300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech).
- Trial name
- NCT05057182
- Testing
- BNT162b2
- Where
- Hong Kong
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Cancer
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response…
- Trial name
- NCT04930055
- Testing
- COVID-19 Vaccination
- Where
- 2 sites in United States
- Volunteers
- 2,206 people, healthy volunteers welcome
- Sponsor
- Indiana University
Covid19, Haematological Disorders
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
The UK Medicine and Healthcare products Regulatory Agency (MHRA) granted temporary authorisation to three Covid-19 vaccines in December 2020 and January 2021.
- Conditions
- Covid19, Haematological Disorders, Immune Suppression
- Trial name
- COVAC-IC (NCT04805216)
- Testing
- Blood test
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Covid19, Respiratory Viral Infection
The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents
The aim of the research is to estimate the levels of cellular and humoral immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Moscow residents over 18 years old.
- Trial name
- NCT04898140
- Testing
- SARS-CoV-2 specific IgM and IgG detection, ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins, Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes
- Where
- Russia
- Volunteers
- 5,340 people, healthy volunteers welcome
- Sponsor
- Moscow Department of Health
Covid19
COVID-19 Vaccine Induced Immunity
This study aims to address the following three objectives: 1. Longitudinal evaluation of the development of CMI responses in response to SARS-CoV-2 Vaccine: T cells isolated from the blood of COVID-19 vaccine recipients will be…
- Trial name
- NCT04713163
- Testing
- covid19 vaccine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
SARS-CoV-2 Infection
Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients
In this study nasal fluid (mucosal lining fluid), nose and throat swabs and blood was collected from patients with a confirmed SARS-CoV-2 infection who remained in home isolation, as well as from their household contacts who…
- Trial name
- MuCo (NCT04590352)
- Testing
- nasopharyngeal and throat swab, collection of mucosal lining fluid, blood collection via fingerprick
- Where
- Netherlands
- Volunteers
- 187 people
- Sponsor
- Radboud University Medical Center
Immunity to COVID-19
Immunity After COVID-19 Vaccination
The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after COVID-19 vaccination.
- Trial name
- NCT04883164
- Testing
- Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Plexision
Influenza, COVID-19
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
Background: Influenza (flu) vaccinations are required for all NIH staff members who have direct contact with patients. COVID-19 vaccines are recommended for persons 6 months of age and older.
- Trial name
- NCT04794829
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV-2 Infection
COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells
The current pandemic caused by the newly identified coronavirus responsible for COVID-19 is a major threat to our populations and societies.
- Trial name
- MEMO-COV2 (NCT04402892)
- Testing
- 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ), 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial
The project aims to clarify how immunity to SARS-CoV2 develops in humans and to investigate the possibility of finding patients with a particularly effective, neutralizing antibody response for future treatment.
- Trial name
- CoVUm (NCT04368013)
- Testing
- Extended sampling and procedures
- Where
- 4 sites in Sweden
- Volunteers
- 550 people
- Sponsor
- Johan Normark
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Immunophenotyping Assessment in a COVID-19 Cohort
This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify…
- Trial name
- IMPACC (NCT04378777)
- Testing
- Biological sample collection, Data Collection: Clinical Care Assessments
- Where
- 17 sites in United States
- Volunteers
- 1,227 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)